Taiwan Liposome Company

Last updated: 13.02.2014

twi-logo-2.jpgTaiwan Liposome Company

Taiwan Liposome Company (TLC) is a specialty biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products based on its proprietary drug delivery technologies for improving the treatment of cancers, peripheral arterial disease (PAD), ophthalmology and infectious diseases. Our strengths lie in utilizing lipid-based formulation for the optimization of pharmacokinetics for better efficacy and lower toxicity.  TLC has developed five proprietary technology platforms which are used in nine products, including one marketed product, two products with drug approval and one NCE product in Phase II.

Since its inception in 1997, TLC has received several important awards and government grants. It was chosen among Red Herring Asia top 100 private companies in 2006, and shortlisted for Red Herring Global 100 in 2007.   TLC was publicly listed in Taiwan on 21st December, 2012, and was selected into MSCI Global Small Cap Indices as of 31 May, 2013.



We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here